Medical Technology Pharmaceuticals Regulations 
Bill Of Health
SEPTEMBER 22, 2022
After graduating from law school, she has trained at Hogan Lovells in their Milan office, specializing in pharmaceutical patent litigation. She has previously published articles on synthetic biology regulation and governance, end stage renal disease payment reform, and comparative analyses of learning disorder policy. Louis (USA).
Bill Of Health
MARCH 23, 2023
By Enrique Santamaría Together with the Data Governance Act (DGA) and the General Data Protection Regulation (GDPR), the proposal for a Regulation on the European Health Data Space (EHDS) will most likely form the new regulatory and governance framework for the use of health data in the European Union. health data). If so, how?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
JULY 2, 2018
Most Americans say that pharmaceutical manufacturers, banks, advertisers, energy firms, and tech companies have too much power and influence in today’s American economy, according to Public Attitudes Toward Technology Companies , a research report from the Pew Research Center.
Bill Of Health
SEPTEMBER 16, 2024
She is interested in mass torts, drug product liability, pharmaceutical antitrust, and the administrative law that affects health-related regulations promulgated by agencies. 2026) research interests include innovative medical technologies and chronic disease policy. Rebekah Ninan’s (J.D. Rupa Palanki’s (J.D.
Bill Of Health
SEPTEMBER 20, 2022
New mRNA vaccines, underpinned by decades of public investment , had been authorized by global regulators. Dose shortages elevated the role of pharmaceutical executives. Pharmaceutical corporations hoarded technology that could have helped alleviate scarcity. Private decisions did not match public health need.
Bill Of Health
NOVEMBER 7, 2023
From national disparities across populations, to global inequalities in access, to scarce medical technologies, from ventilators to vaccines, inequalities have been an overriding feature of this pandemic. Deep inequities and discrimination were manifested across the board.
HIT Consultant
AUGUST 18, 2021
In view of this, regulators have demonstrated unprecedented flexibility and collaboration with key industry players to support the delivery of treatments to the market. First, regulators liberally issued Emergency Use Authorizations (EUAs) for COVID-19 products to expedite the testing, treatment, and vaccination of patients.
Expert insights. Personalized for you.
52 
Let's personalize your content